PT771817E - Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso - Google Patents

Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso

Info

Publication number: PT771817E
Authority: PT; Portugal
Prior art keywords: estrogen; obesity; treatment; group; estrone
Prior art date: 1995-10-30

Application number

PT96500140T

Other languages

English (en)

Inventor

Maria Alemany

Original Assignee

Oleoyl Estrone Developments S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-30

Filing date

1996-10-28

Publication date

2003-06-30

1996-10-28 Application filed by Oleoyl Estrone Developments S filed Critical Oleoyl Estrone Developments S

2003-06-30 Publication of PT771817E publication Critical patent/PT771817E/pt

Links

208000008589 Obesity Diseases 0.000 title abstract 2
229940011871 estrogen Drugs 0.000 title abstract 2
239000000262 estrogen Substances 0.000 title abstract 2
235000020824 obesity Nutrition 0.000 title abstract 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 title abstract 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 abstract 1
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 abstract 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 abstract 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
102000004895 Lipoproteins Human genes 0.000 abstract 1
108090001030 Lipoproteins Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
206010033307 Overweight Diseases 0.000 abstract 1
235000021314 Palmitic acid Nutrition 0.000 abstract 1
235000021319 Palmitoleic acid Nutrition 0.000 abstract 1
241000700159 Rattus Species 0.000 abstract 1
235000021355 Stearic acid Nutrition 0.000 abstract 1
IMIPDPVHGGHVNH-YWVHRCQQSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] (z)-octadec-9-enoate Chemical compound C1C[C@]2(C)C(=O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C3[C@H]21 IMIPDPVHGGHVNH-YWVHRCQQSA-N 0.000 abstract 1
210000000577 adipose tissue Anatomy 0.000 abstract 1
235000020661 alpha-linolenic acid Nutrition 0.000 abstract 1
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 1
235000021342 arachidonic acid Nutrition 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
235000014113 dietary fatty acids Nutrition 0.000 abstract 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 abstract 1
229960000452 diethylstilbestrol Drugs 0.000 abstract 1
229960005309 estradiol Drugs 0.000 abstract 1
229930182833 estradiol Natural products 0.000 abstract 1
229960001348 estriol Drugs 0.000 abstract 1
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 abstract 1
229960003399 estrone Drugs 0.000 abstract 1
229960002568 ethinylestradiol Drugs 0.000 abstract 1
229930195729 fatty acid Natural products 0.000 abstract 1
239000000194 fatty acid Substances 0.000 abstract 1
150000004665 fatty acids Chemical class 0.000 abstract 1
238000010253 intravenous injection Methods 0.000 abstract 1
235000020778 linoleic acid Nutrition 0.000 abstract 1
239000002502 liposome Substances 0.000 abstract 1
231100000053 low toxicity Toxicity 0.000 abstract 1
230000003278 mimic effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
235000021313 oleic acid Nutrition 0.000 abstract 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 abstract 1
239000000725 suspension Substances 0.000 abstract 1
210000001519 tissue Anatomy 0.000 abstract 1
239000013585 weight reducing agent Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
- C07C69/58—Esters of straight chain acids with eighteen carbon atoms in the acid moiety
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT96500140T 1995-10-30 1996-10-28 Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso PT771817E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES9502101		1995-10-30

Publications (1)

Publication Number	Publication Date
PT771817E true PT771817E (pt)	2003-06-30

Family

ID=8291993

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT96500140T PT771817E (pt)	1995-10-30	1996-10-28	Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso

Country Status (7)

Country	Link
US (1)	US5798348A (pt)
EP (1)	EP0771817B1 (pt)
AT (1)	ATE235505T1 (pt)
DE (1)	DE69626927T2 (pt)
DK (1)	DK0771817T3 (pt)
ES (1)	ES2192221T3 (pt)
PT (1)	PT771817E (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2321455A (en)	1997-01-24	1998-07-29	Norsk Hydro As	Lipophilic derivatives of biologically active compounds
AU4701299A (en)	1998-06-23	2000-01-10	Stuart R. Adler	Therapeutic applications of estrogenic carboxylic acids
AU3579200A (en) *	1999-02-26	2000-09-14	Saltech I Goteborg Ab	Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1
PT1955700E (pt)	1999-09-30	2011-05-04	Harbor Biosciences Inc	Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
US7025984B1 (en)	2000-06-26	2006-04-11	The Procter & Gamble Company	Compositions and methods for body weight management
AU2005242170B2 (en) *	2000-06-26	2008-12-18	The Procter & Gamble Company	Compositions and methods for body weight management
WO2002069977A1 (en)	2001-03-01	2002-09-12	Hollis-Eden Pharmaceuticals, Inc.	Use of certain steroids for treatment of blood cell deficiencies
ES2173049B1 (es) *	2001-03-28	2004-01-16	Oleoyl Estrone Developments S	Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante.
US6635015B2 (en) *	2001-04-20	2003-10-21	The Procter & Gamble Company	Body weight management system
US7125568B2 (en) *	2001-08-23	2006-10-24	Sung Michael T	Lipophilic drug compositions
US20040157816A1 (en) *	2002-08-26	2004-08-12	Girouard Michael P.	Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents
WO2003018529A1 (en) *	2001-08-24	2003-03-06	Girouard Michael P	Monounsaturated fatty acids of at least 20 carbon atoms and perhydrocyclopentanophenanthrene nucleus combination molecules and their use as weight-loss agents
ES2186576B1 (es) *	2001-10-11	2004-09-16	Universitat De Les Illes Balears	Acido 2-hidroxioleico para utilizar como medicamento.
WO2004045560A2 (en) *	2002-11-20	2004-06-03	Girouard Michael P	Combination of monounsaturated fatty acids and estogen, and their use
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN1964630A (zh)	2003-02-13	2007-05-16	耶希瓦大学艾伯塔·爱恩斯坦医学院	通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
CA2436650A1 (en) *	2003-08-06	2005-02-06	Naturia Inc.	Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
AU2005330504B2 (en)	2004-09-29	2010-10-28	Harbor Biosciences, Inc.	Steroid analogs and characterization and treatment methods
US20060084636A1 (en) *	2004-10-18	2006-04-20	Maria Alemany	Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same
US20060084637A1 (en) *	2004-10-18	2006-04-20	Maria Alemany	Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US7528791B2 (en) *	2005-08-08	2009-05-05	Wistron Neweb Corporation	Antenna structure having a feed element formed on an opposite surface of a substrate from a ground portion and a radiating element
MX2008014870A (es)	2006-05-30	2009-02-12	Intarcia Therapeutics Inc	Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
WO2008147373A2 (en) *	2006-06-26	2008-12-04	Manhattan Pharmaceuticals, Inc.	Methods and compositions for reducing body weight using an estrogen fatty ester in an oil
EP2049081B1 (en)	2006-08-09	2012-11-14	Intarcia Therapeutics, Inc.	Osmotic delivery systems and piston assemblies
ES2302449B1 (es) *	2006-10-30	2009-06-12	Oleoyl-Estrone Developments, S.L.	Monoesteres de estrogenos con acido linoleico conjugado y usos de los mismos.
HRP20130259T1 (hr)	2007-04-23	2013-04-30	Intarcia Therapeutics, Inc.	Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
EP2085089A1 (en) *	2008-02-01	2009-08-05	KTB-Tumorforschungs GmbH	Phospholipids Containing omega-3-Fatty Acids for the Treatment of Overweight, Obesity and Addictive Behavior
DK2240155T3 (da)	2008-02-13	2012-09-17	Intarcia Therapeutics Inc	Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
SMT201700583T1 (it)	2009-09-28	2018-01-11	Intarcia Therapeutics Inc	Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140378424A1 (en) *	2011-12-30	2014-12-25	Rosscreening, Inc.	Estrogen receptor modulators for reducing body weight
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en)	2015-06-03	2021-02-23	Intarcia Therapeutics, Inc.	Implant placement and removal systems
RU2760007C2 (ru)	2016-05-16	2021-11-22	Интарсия Терапьютикс, Инк.	Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
CN110225762A (zh)	2017-01-03	2019-09-10	因塔西亚制药公司	包括glp-1受体激动剂的连续施用和药物的共同施用的方法
US10836788B2 (en)	2019-02-05	2020-11-17	SD Chem, Inc.	Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2265976A (en) *	1937-10-25	1941-12-09	Schering Corp	Tertiary alcohols of the estrane series and their derivatives and a process for their manufacture
GB531178A (en) *	1938-07-02	1940-12-31	Chem Ind Basel	Manufacture of new esters of the oxy-stilbene series
JPH0610127B2 (ja) *	1985-02-09	1994-02-09	ライオン株式会社	養毛料
US4617298A (en) *	1985-10-22	1986-10-14	University Of Florida	Method and compositions for weight control

1996
- 1996-10-28 ES ES96500140T patent/ES2192221T3/es not_active Expired - Lifetime
- 1996-10-28 DK DK96500140T patent/DK0771817T3/da active
- 1996-10-28 EP EP96500140A patent/EP0771817B1/en not_active Expired - Lifetime
- 1996-10-28 PT PT96500140T patent/PT771817E/pt unknown
- 1996-10-28 AT AT96500140T patent/ATE235505T1/de not_active IP Right Cessation
- 1996-10-28 DE DE69626927T patent/DE69626927T2/de not_active Expired - Lifetime
- 1996-10-30 US US08/739,165 patent/US5798348A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69626927T2 (de)	2003-11-20
US5798348A (en)	1998-08-25
DK0771817T3 (da)	2003-07-28
DE69626927D1 (de)	2003-04-30
ATE235505T1 (de)	2003-04-15
EP0771817A3 (en)	1999-04-14
EP0771817B1 (en)	2003-03-26
EP0771817A2 (en)	1997-05-07
ES2192221T3 (es)	2003-10-01

Publication	Publication Date	Title
PT771817E (pt)	2003-06-30	Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso
McMurchie et al.	1990	Incorporation and effects of dietary eicosapentaenoate (20: 5 (n− 3)) on plasma and erythrocyte lipids of the marmoset following dietary supplementation with differing levels of linoleic acid
Zampolli et al.	2006	Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models
Wargovich et al.	1984	Calcium inhibits the damaging and compensatory proliferative effects of fatty acids on mouse colon epithelium
Bourre et al.	1988	High dietary fish oil alters the brain polyunsaturated fatty acid composition
BR9803195A (pt)	2000-01-11	Produto alimentìcio à base de gordura,e, pasta de gordura amarela de espalhar.
NO920067L (no)	1992-07-15	Foradditiv for droevtyggere
BR0307101A (pt)	2004-12-28	Fracionamento de ésteres de fitosterol em óleo
ES2074734T5 (es)	2002-02-16	Utilizacion de composiciones a base de alcoholes grasos, para la preparacion de emulsiones; procedimiento de preparacion de emulsiones y emulsiones asi obtenidas.
EP1072249A3 (de)	2004-01-21	Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
IE63303B1 (en)	1995-04-05	Essential fatty acid compositions
KR960010832B1 (ko)	1996-08-09	필수지방산 합성물(Essential Fatty Acid Compositins)
DE69625616T3 (de)	2010-07-08	Lipidemulsionen mit optimierter hydrolyse sowie deren verwendung
Williams et al.	1968	Effects of dietary fat level on pantothenate depletion and liver fatty acid composition in the rat
ATE93722T1 (de)	1993-09-15	Omega-3-fettsaeurenhaltige fettemulsion zur endotrachealen applikation, ihre herstellung und anwendung.
Larue et al.	1970	Effect of the removal of olfactory bulbs upon hyperphagia and obesity induced in rats by VMH lesion
EP0444033A1 (de)	1991-09-04	Topische kosmetische und pharmazeutische zubereitung
US5484611A (en)	1996-01-16	Method of producing a fatty acid
Leaf et al.	1999	Experimental studies on antiarrhythmic and antiseizure effects of polyunsaturated fatty acids in excitable tissues
WO2004045560A3 (en)	2004-07-29	Combination of monounsaturated fatty acids and estogen, and their use
ES2059827T3 (es)	1994-11-16	Emulsion para administracion parenteral.
Peterson et al.	1954	Effects of dietary sterols and sterol esters on plasma and liver cholesterol in the chick
KR920021151A (ko)	1992-12-18	면역억제특성을 갖는 약제학적 조성물을 제조하기 위한 인지질 유도체의 용도
RU2052947C1 (ru)	1996-01-27	Масложировой продукт, имеющий иммуностимулирующие свойства
Craig et al.	1968	Nutritional properties of Canadian canbra oil